why ADMA Biologics Inc. [ADMA] is a Good Choice for Investors After New Price Target of $5.58

Related

Share

ADMA Biologics Inc. [NASDAQ: ADMA] loss -4.00% or -0.05 points to close at $1.20 with a heavy trading volume of 3535729 shares. The company report on December 21, 2021 that ADMA Biologics Adopts Limited Duration Stockholder Rights Plan.

ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption of a 6-month term stockholder rights plan (the “Rights Plan”) and declared a dividend distribution of one right (the “Right”) for each outstanding share of common stock. The record date for the dividend distribution is December 30, 2021. The Rights Plan will expire, without any further action required to be taken by ADMA’s Board of Directors, on June 15, 2022.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


ADMA is in the process of evaluating a variety of strategic and financial alternatives and this assessment is occurring alongside the previously announced and ongoing Morgan Stanley-led strategic process review. The adoption of the Rights Plan is intended to help facilitate this review in order to protect both ADMA and its stockholders from the actions of third parties that ADMA’s Board of Directors determines to be not in the best interests of ADMA and its stockholders, and to enable all stockholders to realize the full potential value of their investment in ADMA.

It opened the trading session at $1.24, the shares rose to $1.27 and dropped to $1.18, the range by which the price of stock traded the whole day. The daily chart for ADMA points out that the company has recorded -25.93% loss over the past six months. However, it is still -18.81% lower than its most recent low trading price.

If we look at the average trading volume of 2.50M shares, ADMA reached to a volume of 3535729 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about ADMA Biologics Inc. [ADMA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADMA shares is $5.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADMA stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Raymond James have made an estimate for ADMA Biologics Inc. shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on November 11, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on November 09, 2021, representing the official price target for ADMA Biologics Inc. stock. Previously, the target price had yet another raise to $8, while Jefferies analysts kept a Buy rating on ADMA stock. On April 15, 2019, analysts increased their price target for ADMA shares from 10 to 13.

The Average True Range (ATR) for ADMA Biologics Inc. is set at 0.09, with the Price to Sales ratio for ADMA stock in the period of the last 12 months amounting to 3.48. The Price to Book ratio for the last quarter was 1.56, with the Price to Cash per share for the same quarter was set at 0.17.

Trading performance analysis for ADMA stock

ADMA Biologics Inc. [ADMA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.69. With this latest performance, ADMA shares dropped by -17.24% in over the last four-week period, additionally sinking by -25.93% over the last 6 months – not to mention a drop of -42.03% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADMA stock in for the last two-week period is set at 38.17, with the RSI for the last a single of trading hit 32.71, and the three-weeks RSI is set at 41.66 for ADMA Biologics Inc. [ADMA]. The present Moving Average for the last 50 days of trading for this stock 1.3536, while it was recorded at 1.2620 for the last single week of trading, and 1.5204 for the last 200 days.

ADMA Biologics Inc. [ADMA]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and ADMA Biologics Inc. [ADMA] shares currently have an operating margin of -153.75 and a Gross Margin at -46.87. ADMA Biologics Inc.’s Net Margin is presently recorded at -179.41.

Return on Total Capital for ADMA is now -43.74, given the latest momentum, and Return on Invested Capital for the company is -51.14. Return on Equity for this stock declined to -132.38, with Return on Assets sitting at -45.25. When it comes to the capital structure of this company, ADMA Biologics Inc. [ADMA] has a Total Debt to Total Equity ratio set at 110.67. Additionally, ADMA Total Debt to Total Capital is recorded at 52.53, with Total Debt to Total Assets ending up at 47.03. Long-Term Debt to Equity for the company is recorded at 110.26, with the Long-Term Debt to Total Capital now at 52.34.

Reflecting on the efficiency of the workforce at the company, ADMA Biologics Inc. [ADMA] managed to generate an average of -$186,114 per employee. Receivables Turnover for the company is 5.05 with a Total Asset Turnover recorded at a value of 0.25.ADMA Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 5.40.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at ADMA Biologics Inc. [ADMA]

There are presently around $52 million, or 24.00% of ADMA stock, in the hands of institutional investors. The top three institutional holders of ADMA stocks are: PERCEPTIVE ADVISORS LLC with ownership of 13,262,375, which is approximately -20.033% of the company’s market cap and around 1.90% of the total institutional ownership; NUVEEN ASSET MANAGEMENT, LLC, holding 6,884,640 shares of the stock with an approximate value of $8.61 million in ADMA stocks shares; and VANGUARD GROUP INC, currently with $7.15 million in ADMA stock with ownership of nearly 2.035% of the company’s market capitalization.

Positions in ADMA Biologics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 25 institutional holders increased their position in ADMA Biologics Inc. [NASDAQ:ADMA] by around 5,984,854 shares. Additionally, 49 investors decreased positions by around 7,016,632 shares, while 21 investors held positions by with 28,790,722 shares. The mentioned changes placed institutional holdings at 41,792,208 shares, according to the latest SEC report filing. ADMA stock had 6 new institutional investments in for a total of 203,570 shares, while 23 institutional investors sold positions of 1,394,955 shares during the same period.